FierceBiotechOriginal article
{"a":[{"_":"Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags","$":{"href":"/biotech/autoimmune-car-t-peers-hit-safety-snags-kyverna-touts-1-year-miv-cel-data","hreflang":"en"}}]}
Data Readoutpositivemiv-celPositive
AI Analysis
Summary
Kyverna Therapeutics reported 1-year clinical data for miv-cel demonstrating sustained efficacy and strong safety profile as competitors in autoimmune CAR-T space face safety challenges.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
1-year data showing sustained efficacy and unblemished safety profile
Importance:6/10
Sentiment:
0.70
CAR-Tautoimmuneclinical datasafetyfirst-in-class
Related Companies
Read the original article
Published by FierceBiotech on September 23, 2026 4:18 PM
